A clinical trial update was recorded on November 4, 2026, for a study registered as NCT07916116. The trial is titled "Oral Gabapentin Versus Intravenous Neostigmine/Atropine Versus Combination of Both for Prevention of PDPH." It is listed as Phase 2/Phase 3 and its current status is recruiting.
The study is registered on ClinicalTrials.gov under the identifier NCT07916116. According to the listing, the trial is designed to compare three approaches for prevention of PDPH: oral gabapentin alone, intravenous neostigmine combined with atropine, and a combination of both regimens. No outcomes or results have been posted for this trial at this time.
This update reflects only the recruitment status and trial design as registered. It does not indicate any findings, efficacy data, or safety conclusions, since none have been reported in the listing. Cosyntropin is noted as an approved compound in this context, though this particular trial entry does not describe cosyntropin's role within the study design based on the information provided.
Readers interested in background on cosyntropin can consult the compound overview for additional context.